Pharma Stocks Are Down But There Is Still Value To Be Unlocked
Pharma Stocks Are Down But There Is Still Value To Be Unlocked. Consider the following:
- Big pharma stocks were down 4%-9% in the first 7 trading days of 2016
- Temporary dip due to S&P 500 falling by ~7% due to China’s economical woes
- Nevertheless, Trefis coverage universe shows upside potential of 3% -27% for big pharma stocks
See our complete analysis for Merck, Pfizer, Johnson & Johnson, Roche and Bristol-Myers Squibb for better understanding of Trefis price estimate for these firms.
Have questions about Roche? See the links below.
- What Drove 15% Growth in Roche’s Earnings Between 2011-2014 Even Though Other Big Pharma Companies Suffered A Decline?
- Why Is Market Assigning Low Earnings Multiple To Roche Despite Its Biotech Focus?
- Can Roche Grow Its Earnings By 15% In The Next 3 Years?
- With Biosimilars Getting Approval In Europe, Does Roche’s 2016 EPS Face A Meaningful Risk?
- How Can Roche Get 25% Boost In Revenues In 5 Years?
- Can Emerging Biosimilar Competition Cause > 10% Downside To Roche’s Valuation?
- Here Is Why We Are Bullish On Roche
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)